ADVANCED WOUND CARE

The MolecuLight i:X Wound Imaging Device allows clinicians to quickly, safely, and easily visualize bacteria 2 and measure wounds 7 at the point of care, so they have maximum insights for accurate treatment selection and accelerated healing. CASE STUDY. WOUND ASSESSMENT TOOL The use of the MolecuLight i:X in managing burns: a pilot study. Journal of Burn Care & Research, 2017, 39 (1), 154-161. doi: 10.1097/BCR.0000000000000565. Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Presented

at Wounds UK 2016.

CLINICAL IMAGE GALLERY OF FLUORESCENCE IMAGES Clinical Image Gallery of Fluorescence Images. Below are a series of images/videos highlighting how the MolecuLight i:X helped clinicians detect fluorescent bacteria and measure wounds to facilitate evidence-based clinician decision making. Search for:

PRESS RELEASES

Press Release: MolecuLight receives $990,000 from FedDev Ontario to complete commercialization of a new clinical wound imaging technology. November 7, 2014 — PRESS RELEASE. Press Release: MolecuLight announces research collaboration

VISUALIZE BACTERIA

The MolecuLight i:X is a handheld fluorescence imaging device that provides instant visual detection and documentation of potentially harmful bacteria in wounds that would otherwise be invisible. 1 The MolecuLight i:X emits a precise wavelength of safe violet light, which interacts with the wound tissue and bacteria causing the wound and MOLECULIGHT DARKDRAPE The MolecuLight DarkDrape is a one-time use consumable that easily connects to the MolecuLight i:X with a built-in adapter. The DarkDrape is made of flexible polyethylene material that contours around any body part while the built-in adapter features a support frame to maintain an unobstructed field of view, enabling fast and easy imaging

of

A PROSPECTIVE MULTISITE OBSERVATIONAL STUDY INCORPORATING ABSTRACT Introduction. The UPPER/LOWER infection checklists look for signs and symptoms of local/superficial infection (UPPER) and deep infection (LOWER) to assist clinicians in identifying and distinguishing between these infection levels, facilitating appropriate treatment. The presence of 3 or more UPPER or LOWER criteria is indicative of infection. Objective. This study evaluated

the

MOELLEKEN M ET AL. INTERNATIONAL WOUND JOURNAL (2020) Continued >> Illuminating the Evidence Publication Summary Prospective clinical study on the efficacy of bacterial removal with mechanical debridement in and around

ADVANCED WOUND CARE

Intended Use & Indication for Use. The MolecuLight i:X is intended for use as a handheld imaging tool that allows clinicians diagnosing and treating skin wounds, at the point of care, to: (iii) View and digitally record images of fluorescence emitted from a wound when exposed to an excitation light. REIMBURSEMENT PATHWAY FOR FLUORESCENCE IMAGING AND Reimbursement Pathway for Fluorescence Imaging and Detection of Wounds Containing Bacterial Burden (>104 CFU/g)* * when used in combination with clinical signs and symptoms There are CPT codes and an APC assignment specific to the procedure for “fluorescence wound imaging for bacterial presence, location, and load”1,2. The MolecuLight i:X® is the only fluorescence imaging device

ADVANCED WOUND CARE

The MolecuLight i:X Wound Imaging Device allows clinicians to quickly, safely, and easily visualize bacteria 2 and measure wounds 7 at the point of care, so they have maximum insights for accurate treatment selection and accelerated healing. CASE STUDY. WOUND ASSESSMENT TOOL The use of the MolecuLight i:X in managing burns: a pilot study. Journal of Burn Care & Research, 2017, 39 (1), 154-161. doi: 10.1097/BCR.0000000000000565. Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Presented

at Wounds UK 2016.

CLINICAL IMAGE GALLERY OF FLUORESCENCE IMAGES Clinical Image Gallery of Fluorescence Images. Below are a series of images/videos highlighting how the MolecuLight i:X helped clinicians detect fluorescent bacteria and measure wounds to facilitate evidence-based clinician decision making. Search for:

PRESS RELEASES

Press Release: MolecuLight receives $990,000 from FedDev Ontario to complete commercialization of a new clinical wound imaging technology. November 7, 2014 — PRESS RELEASE. Press Release: MolecuLight announces research collaboration

VISUALIZE BACTERIA

The MolecuLight i:X is a handheld fluorescence imaging device that provides instant visual detection and documentation of potentially harmful bacteria in wounds that would otherwise be invisible. 1 The MolecuLight i:X emits a precise wavelength of safe violet light, which interacts with the wound tissue and bacteria causing the wound and MOLECULIGHT DARKDRAPE The MolecuLight DarkDrape is a one-time use consumable that easily connects to the MolecuLight i:X with a built-in adapter. The DarkDrape is made of flexible polyethylene material that contours around any body part while the built-in adapter features a support frame to maintain an unobstructed field of view, enabling fast and easy imaging

of

A PROSPECTIVE MULTISITE OBSERVATIONAL STUDY INCORPORATING ABSTRACT Introduction. The UPPER/LOWER infection checklists look for signs and symptoms of local/superficial infection (UPPER) and deep infection (LOWER) to assist clinicians in identifying and distinguishing between these infection levels, facilitating appropriate treatment. The presence of 3 or more UPPER or LOWER criteria is indicative of infection. Objective. This study evaluated

the

MOELLEKEN M ET AL. INTERNATIONAL WOUND JOURNAL (2020) Continued >> Illuminating the Evidence Publication Summary Prospective clinical study on the efficacy of bacterial removal with mechanical debridement in and around

ADVANCED WOUND CARE

Intended Use & Indication for Use. The MolecuLight i:X is intended for use as a handheld imaging tool that allows clinicians diagnosing and treating skin wounds, at the point of care, to: (iii) View and digitally record images of fluorescence emitted from a wound when exposed to an excitation light. REIMBURSEMENT PATHWAY FOR FLUORESCENCE IMAGING AND Reimbursement Pathway for Fluorescence Imaging and Detection of Wounds Containing Bacterial Burden (>104 CFU/g)* * when used in combination with clinical signs and symptoms There are CPT codes and an APC assignment specific to the procedure for “fluorescence wound imaging for bacterial presence, location, and load”1,2. The MolecuLight i:X® is the only fluorescence imaging device

PRESS RELEASES

Press Release: MolecuLight receives $990,000 from FedDev Ontario to complete commercialization of a new clinical wound imaging technology. November 7, 2014 — PRESS RELEASE. Press Release: MolecuLight announces research collaboration WHAT IS THE MOLECULIGHT I:X PROCEDURE? What is the MolecuLight i:X procedure? This 7-minute presentation will cover: How the MolecuLight i:X works. Detecting wounds with elevated bacterial loads. What the wound care clinical workflow looks like with the MolecuLight i:X. Typical cost savings. Reimbursement for the fluorescence imaging procedure. Fluorescence imaging & wound

measurement.

I:X® TELEMEDICINE SOLUTION The use of telemedicine is rapidly increasing in wound care. However, traditional signs and symptoms of infection can be difficult to determine remotely. Access to expert wound care practitioners at the bedside can be increasingly limited, especially in long term care facilities and homecare clinics, or when travel by specialists is challenging, such as in MOLECULIGHT EXECUTIVE TEAM MolecuLight Inc. is a privately owned, Canadian medical imaging company founded by Dr. Ralph DaCosta and incorporated on June 1, 2012. The company’s first product, the MolecuLight i:X, is a first-of-its kind handheld imaging device based on Dr. DaCosta’s invention. MolecuLight is based in Toronto, Canada. MOLECULIGHT ANNOUNCES CMS HAS ASSIGNED AN APC New Code Enables Reimbursement to Hospital Outpatient Centers Using MolecuLight i:X Toronto, CANADA – (June 11, 2020) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces that the Centers for Medicare & Medicaid Services (CMS) has assigned an Ambulatory Payment Classification (APC) code 5722 for the MolecuLight FREQUENTLY ASKED QUESTIONS (FAQ) In a darkened room, or using a DarkDrape™, the MolecuLight i:X shines a safe violet excitation light (405 nm) on a wound. This causes wound components (skin, slough, blood, bacteria, etc.) to fluoresce (or emit light) in different colours 1–4 .The i:X device displays and captures images of the most informative of these fluorescent

colours.

UTILITY OF MOLECULIGHT FOR WOUND CARE PATIENTS The MolecuLight i:X is a hand-held imaging device that uses a safe violet light to help wound care professionals detect bacteria in your wound and to measure the size of your wound.. The MolecuLight i:X captures both images and videos that can be saved with your medical records to track how your wound is healing. Taking images with the MolecuLight i:X gives your wound care provider information COST-SAVINGS/ REIMBURSEMENT F luorescence imaging was more accurate than clinical judgement in detecting elevated bacterial loads. $ 7,660 USD per patient was the estimated cost savings from using fluorescence imaging information. T his information avoided the application of cellular tissue products on wounds with high levels of bacteria. MOLECULIGHT I:X QUICK START GUIDE a. Ensurei:X is OFF or turn device OFF and Display Screen OFF. b. Use a disinfecting wipe to preclean the i:X. d. Use lens towelette to clean all glass surfaces. e. Check that all windows are

ADVANCED WOUND CARE

1 American Diabetes Society, Diagnosis and Management of Diabetic Foot Infections, 2020 2 Heather L. Orsted et al., Foundations of Best Practice for Skin and Wound Management Skin: Anatomy, Physiology and Wound Healing 3 Robson MC et al., Guidelines for the treatment of venous ulcers. Wound Repair Regen. 2006 Nov-Dec;14(6):649-62 4 Emily Haesler et al., National Pressure Ulcer Advisory Panel

ADVANCED WOUND CARE

The MolecuLight i:X Wound Imaging Device allows clinicians to quickly, safely, and easily visualize bacteria 2 and measure wounds 7 at the point of care, so they have maximum insights for accurate treatment selection and accelerated healing. CASE STUDY. WOUND ASSESSMENT TOOL The use of the MolecuLight i:X in managing burns: a pilot study. Journal of Burn Care & Research, 2017, 39 (1), 154-161. doi: 10.1097/BCR.0000000000000565. Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Presented

at Wounds UK 2016.

CLINICAL IMAGE GALLERY OF FLUORESCENCE IMAGES Clinical Image Gallery of Fluorescence Images. Below are a series of images/videos highlighting how the MolecuLight i:X helped clinicians detect fluorescent bacteria and measure wounds to facilitate evidence-based clinician decision making. Search for:

VISUALIZE BACTERIA

The MolecuLight i:X is a handheld fluorescence imaging device that provides instant visual detection and documentation of potentially harmful bacteria in wounds that would otherwise be invisible. 1 The MolecuLight i:X emits a precise wavelength of safe violet light, which interacts with the wound tissue and bacteria causing the wound and MOLECULIGHT ANNOUNCES CMS HAS ASSIGNED AN APC New Code Enables Reimbursement to Hospital Outpatient Centers Using MolecuLight i:X Toronto, CANADA – (June 11, 2020) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces that the Centers for Medicare & Medicaid Services (CMS) has assigned an Ambulatory Payment Classification (APC) code 5722 for the MolecuLight i:X

WOUNDSOURCE WEBINAR

The MolecuLight i:X for point-of-care detection of elevated bacterial burden in wounds – in real-time A PROSPECTIVE MULTISITE OBSERVATIONAL STUDY INCORPORATING ABSTRACT Introduction. The UPPER/LOWER infection checklists look for signs and symptoms of local/superficial infection (UPPER) and deep infection (LOWER) to assist clinicians in identifying and distinguishing between these infection levels, facilitating appropriate treatment. The presence of 3 or more UPPER or LOWER criteria is indicative of infection. Objective. This study evaluated

the

POINT OF CARE IDENTIFICATION Point of Care Identification of. Pseudomonas Aeruginosa. Case Study. Pseudomonas aeruginosa is one of the most common pathogens found in chronic leg ulcers. 1 It frequently leads to stalled wound healing and its unique intrinsic and acquired antibiotic resistances make early identification and selection of Pseudomonas -specific treatment

ADVANCED WOUND CARE

Intended Use & Indication for Use. The MolecuLight i:X is intended for use as a handheld imaging tool that allows clinicians diagnosing and treating skin wounds, at the point of care, to: (iii) View and digitally record images of fluorescence emitted from a wound when exposed to an excitation light. MOLECULIGHT I:X QUICK START GUIDE a. Ensurei:X is OFF or turn device OFF and Display Screen OFF. b. Use a disinfecting wipe to preclean the i:X. d. Use lens towelette to clean all glass surfaces. e. Check that all windows are

ADVANCED WOUND CARE

The MolecuLight i:X Wound Imaging Device allows clinicians to quickly, safely, and easily visualize bacteria 2 and measure wounds 7 at the point of care, so they have maximum insights for accurate treatment selection and accelerated healing. CASE STUDY. WOUND ASSESSMENT TOOL The use of the MolecuLight i:X in managing burns: a pilot study. Journal of Burn Care & Research, 2017, 39 (1), 154-161. doi: 10.1097/BCR.0000000000000565. Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Presented

at Wounds UK 2016.

CLINICAL IMAGE GALLERY OF FLUORESCENCE IMAGES Clinical Image Gallery of Fluorescence Images. Below are a series of images/videos highlighting how the MolecuLight i:X helped clinicians detect fluorescent bacteria and measure wounds to facilitate evidence-based clinician decision making. Search for:

VISUALIZE BACTERIA

The MolecuLight i:X is a handheld fluorescence imaging device that provides instant visual detection and documentation of potentially harmful bacteria in wounds that would otherwise be invisible. 1 The MolecuLight i:X emits a precise wavelength of safe violet light, which interacts with the wound tissue and bacteria causing the wound and MOLECULIGHT ANNOUNCES CMS HAS ASSIGNED AN APC New Code Enables Reimbursement to Hospital Outpatient Centers Using MolecuLight i:X Toronto, CANADA – (June 11, 2020) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces that the Centers for Medicare & Medicaid Services (CMS) has assigned an Ambulatory Payment Classification (APC) code 5722 for the MolecuLight i:X

WOUNDSOURCE WEBINAR

The MolecuLight i:X for point-of-care detection of elevated bacterial burden in wounds – in real-time A PROSPECTIVE MULTISITE OBSERVATIONAL STUDY INCORPORATING ABSTRACT Introduction. The UPPER/LOWER infection checklists look for signs and symptoms of local/superficial infection (UPPER) and deep infection (LOWER) to assist clinicians in identifying and distinguishing between these infection levels, facilitating appropriate treatment. The presence of 3 or more UPPER or LOWER criteria is indicative of infection. Objective. This study evaluated

the

POINT OF CARE IDENTIFICATION Point of Care Identification of. Pseudomonas Aeruginosa. Case Study. Pseudomonas aeruginosa is one of the most common pathogens found in chronic leg ulcers. 1 It frequently leads to stalled wound healing and its unique intrinsic and acquired antibiotic resistances make early identification and selection of Pseudomonas -specific treatment

ADVANCED WOUND CARE

Intended Use & Indication for Use. The MolecuLight i:X is intended for use as a handheld imaging tool that allows clinicians diagnosing and treating skin wounds, at the point of care, to: (iii) View and digitally record images of fluorescence emitted from a wound when exposed to an excitation light. MOLECULIGHT I:X QUICK START GUIDE a. Ensurei:X is OFF or turn device OFF and Display Screen OFF. b. Use a disinfecting wipe to preclean the i:X. d. Use lens towelette to clean all glass surfaces. e. Check that all windows are WHAT IS THE MOLECULIGHT I:X PROCEDURE? What is the MolecuLight i:X procedure? This 7-minute presentation will cover: How the MolecuLight i:X works. Detecting wounds with elevated bacterial loads. What the wound care clinical workflow looks like with the MolecuLight i:X. Typical cost savings. Reimbursement for the fluorescence imaging procedure. Fluorescence imaging & wound

measurement.

MOLECULIGHT EXECUTIVE TEAM MolecuLight Inc. is a privately owned, Canadian medical imaging company founded by Dr. Ralph DaCosta and incorporated on June 1, 2012. The company’s first product, the MolecuLight i:X, is a first-of-its kind handheld imaging device based on Dr. DaCosta’s invention. MolecuLight is based in Toronto, Canada. FREQUENTLY ASKED QUESTIONS (FAQ) In a darkened room, or using a DarkDrape™, the MolecuLight i:X shines a safe violet excitation light (405 nm) on a wound. This causes wound components (skin, slough, blood, bacteria, etc.) to fluoresce (or emit light) in different colours 1–4 .The i:X device displays and captures images of the most informative of these fluorescent

colours.

NOVEL TECHNOLOGY TO HELP IMPROVE WOUND CARE IN CANADA Results of Clinical Integration Project of MolecuLight i:X® Point-of-Care Imaging Device Illustrate Improved Access, Effectiveness and Efficiency of Wound Care TORONTO, Ontario – (May 18, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, is helping to improve wound care in Canada with the only point-of

WOUNDSOURCE WEBINAR

The MolecuLight i:X for point-of-care detection of elevated bacterial burden in wounds – in real-time MOLECULIGHT RECEIVES FDA 510K CLEARANCE FOR I:X FDA Approval Extends Label to Include MolecuLight i:X Wound Care Device Features TORONTO, Canada – (December 5, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of fluorescence in wounds, has received FDA 510(k) clearance for its i:X® handheld fluorescence imaging device for use in the detection of wounds containing bacteria. UTILITY OF MOLECULIGHT FOR WOUND CARE PATIENTS The MolecuLight i:X is a hand-held imaging device that uses a safe violet light to help wound care professionals detect bacteria in your wound and to measure the size of your wound.. The MolecuLight i:X captures both images and videos that can be saved with your medical records to track how your wound is healing. Taking images with the MolecuLight i:X gives your wound care provider information MOLECULIGHT I:XTM USER MANUAL MolecuLight i:XTM User Manual Revision 1.0 Page 6 of 43 Warning The MolecuLight i:X Imaging Device comes fully assembled and ready for use. No modification of this equipment is allowed. Modification of the device will void the terms of the warranty. WOUND HEALING: WHAT IS THE NICE GUIDANCE FROM THE UK Abstract Alteration of wound healing increases the risk of a patient’s morbidity and mortality. This can lead to scarring, infection, malignant transformation and a reduction in quality of life. Management of wounds costs the UK an estimated £5.3 billion annually which is paid for by the state, with further financial burden due to health related

WOUNDSOURCE WEBINAR

View details on the Reimbursement Pathway for the MolecuLight procedure, as well as CME Resources, Training & Education support and

Clinical Research.

ADVANCED WOUND CARE

The MolecuLight i:X Wound Imaging Device allows clinicians to quickly, safely, and easily visualize bacteria 2 and measure wounds 7 at the point of care, so they have maximum insights for accurate treatment selection and accelerated healing. CASE STUDY. WOUND ASSESSMENT TOOL The use of the MolecuLight i:X in managing burns: a pilot study. Journal of Burn Care & Research, 2017, 39 (1), 154-161. doi: 10.1097/BCR.0000000000000565. Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Presented

at Wounds UK 2016.

CLINICAL IMAGE GALLERY OF FLUORESCENCE IMAGES Clinical Image Gallery of Fluorescence Images. Below are a series of images/videos highlighting how the MolecuLight i:X helped clinicians detect fluorescent bacteria and measure wounds to facilitate evidence-based clinician decision making. Search for:

VISUALIZE BACTERIA

The MolecuLight i:X is a handheld fluorescence imaging device that provides instant visual detection and documentation of potentially harmful bacteria in wounds that would otherwise be invisible. 1 The MolecuLight i:X emits a precise wavelength of safe violet light, which interacts with the wound tissue and bacteria causing the wound and

WOUNDSOURCE WEBINAR

The MolecuLight i:X for point-of-care detection of elevated bacterial burden in wounds – in real-time MOLECULIGHT ANNOUNCES CMS HAS ASSIGNED AN APC New Code Enables Reimbursement to Hospital Outpatient Centers Using MolecuLight i:X Toronto, CANADA – (June 11, 2020) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces that the Centers for Medicare & Medicaid Services (CMS) has assigned an Ambulatory Payment Classification (APC) code 5722 for the MolecuLight i:X A PROSPECTIVE MULTISITE OBSERVATIONAL STUDY INCORPORATING ABSTRACT Introduction. The UPPER/LOWER infection checklists look for signs and symptoms of local/superficial infection (UPPER) and deep infection (LOWER) to assist clinicians in identifying and distinguishing between these infection levels, facilitating appropriate treatment. The presence of 3 or more UPPER or LOWER criteria is indicative of infection. Objective. This study evaluated

the

POINT OF CARE IDENTIFICATION Point of Care Identification of. Pseudomonas Aeruginosa. Case Study. Pseudomonas aeruginosa is one of the most common pathogens found in chronic leg ulcers. 1 It frequently leads to stalled wound healing and its unique intrinsic and acquired antibiotic resistances make early identification and selection of Pseudomonas -specific treatment

ADVANCED WOUND CARE

Intended Use & Indication for Use. The MolecuLight i:X is intended for use as a handheld imaging tool that allows clinicians diagnosing and treating skin wounds, at the point of care, to: (iii) View and digitally record images of fluorescence emitted from a wound when exposed to an excitation light. REIMBURSEMENT PATHWAY FOR FLUORESCENCE IMAGING AND Reimbursement Pathway for Fluorescence Imaging and Detection of Wounds Containing Bacterial Burden (>104 CFU/g)* * when used in combination with clinical signs and symptoms There are CPT codes and an APC assignment specific to the procedure for “fluorescence wound imaging for bacterial presence, location, and load”1,2. The MolecuLight i:X® is the only fluorescence imaging device

ADVANCED WOUND CARE

The MolecuLight i:X Wound Imaging Device allows clinicians to quickly, safely, and easily visualize bacteria 2 and measure wounds 7 at the point of care, so they have maximum insights for accurate treatment selection and accelerated healing. CASE STUDY. WOUND ASSESSMENT TOOL The use of the MolecuLight i:X in managing burns: a pilot study. Journal of Burn Care & Research, 2017, 39 (1), 154-161. doi: 10.1097/BCR.0000000000000565. Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Presented

at Wounds UK 2016.

CLINICAL IMAGE GALLERY OF FLUORESCENCE IMAGES Clinical Image Gallery of Fluorescence Images. Below are a series of images/videos highlighting how the MolecuLight i:X helped clinicians detect fluorescent bacteria and measure wounds to facilitate evidence-based clinician decision making. Search for:

VISUALIZE BACTERIA

The MolecuLight i:X is a handheld fluorescence imaging device that provides instant visual detection and documentation of potentially harmful bacteria in wounds that would otherwise be invisible. 1 The MolecuLight i:X emits a precise wavelength of safe violet light, which interacts with the wound tissue and bacteria causing the wound and

WOUNDSOURCE WEBINAR

The MolecuLight i:X for point-of-care detection of elevated bacterial burden in wounds – in real-time MOLECULIGHT ANNOUNCES CMS HAS ASSIGNED AN APC New Code Enables Reimbursement to Hospital Outpatient Centers Using MolecuLight i:X Toronto, CANADA – (June 11, 2020) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces that the Centers for Medicare & Medicaid Services (CMS) has assigned an Ambulatory Payment Classification (APC) code 5722 for the MolecuLight i:X A PROSPECTIVE MULTISITE OBSERVATIONAL STUDY INCORPORATING ABSTRACT Introduction. The UPPER/LOWER infection checklists look for signs and symptoms of local/superficial infection (UPPER) and deep infection (LOWER) to assist clinicians in identifying and distinguishing between these infection levels, facilitating appropriate treatment. The presence of 3 or more UPPER or LOWER criteria is indicative of infection. Objective. This study evaluated

the

POINT OF CARE IDENTIFICATION Point of Care Identification of. Pseudomonas Aeruginosa. Case Study. Pseudomonas aeruginosa is one of the most common pathogens found in chronic leg ulcers. 1 It frequently leads to stalled wound healing and its unique intrinsic and acquired antibiotic resistances make early identification and selection of Pseudomonas -specific treatment

ADVANCED WOUND CARE

Intended Use & Indication for Use. The MolecuLight i:X is intended for use as a handheld imaging tool that allows clinicians diagnosing and treating skin wounds, at the point of care, to: (iii) View and digitally record images of fluorescence emitted from a wound when exposed to an excitation light. REIMBURSEMENT PATHWAY FOR FLUORESCENCE IMAGING AND Reimbursement Pathway for Fluorescence Imaging and Detection of Wounds Containing Bacterial Burden (>104 CFU/g)* * when used in combination with clinical signs and symptoms There are CPT codes and an APC assignment specific to the procedure for “fluorescence wound imaging for bacterial presence, location, and load”1,2. The MolecuLight i:X® is the only fluorescence imaging device WHAT IS THE MOLECULIGHT I:X PROCEDURE? What is the MolecuLight i:X procedure? This 7-minute presentation will cover: How the MolecuLight i:X works. Detecting wounds with elevated bacterial loads. What the wound care clinical workflow looks like with the MolecuLight i:X. Typical cost savings. Reimbursement for the fluorescence imaging procedure. Fluorescence imaging & wound

measurement.

PRESS RELEASES

Press Release: MolecuLight receives $990,000 from FedDev Ontario to complete commercialization of a new clinical wound imaging technology. November 7, 2014 — PRESS RELEASE. Press Release: MolecuLight announces research collaboration MOLECULIGHT EXECUTIVE TEAM MolecuLight Inc. is a privately owned, Canadian medical imaging company founded by Dr. Ralph DaCosta and incorporated on June 1, 2012. The company’s first product, the MolecuLight i:X, is a first-of-its kind handheld imaging device based on Dr. DaCosta’s invention. MolecuLight is based in Toronto, Canada. FREQUENTLY ASKED QUESTIONS (FAQ) In a darkened room, or using a DarkDrape™, the MolecuLight i:X shines a safe violet excitation light (405 nm) on a wound. This causes wound components (skin, slough, blood, bacteria, etc.) to fluoresce (or emit light) in different colours 1–4 .The i:X device displays and captures images of the most informative of these fluorescent

colours.

AMA ISSUES CATEGORY III CPT CODE FOR REAL TIME Reimbursement Pathway Established for MolecuLight’s i:X Procedure in Wound Care TORONTO, Canada – (February 13, 2020) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time detection of bacteria in wounds, announced that the American Medical Association (AMA) has issued two new CPT category lll codes to enable a reimbursement pathway for point-of UTILITY OF MOLECULIGHT FOR WOUND CARE PATIENTS The MolecuLight i:X is a hand-held imaging device that uses a safe violet light to help wound care professionals detect bacteria in your wound and to measure the size of your wound.. The MolecuLight i:X captures both images and videos that can be saved with your medical records to track how your wound is healing. Taking images with the MolecuLight i:X gives your wound care provider information MOLECULIGHT I:X QUICK START GUIDE a. Ensurei:X is OFF or turn device OFF and Display Screen OFF. b. Use a disinfecting wipe to preclean the i:X. d. Use lens towelette to clean all glass surfaces. e. Check that all windows are THE USE OF THE MOLECULIGHT BACTERIAL CAMERA IN THE Fluorescence imaging targets swabbing to region of bioburden Standard Imaging Mode Fluorescence Imaging Mode 85-year-old male suffered deep dermal and full thickness contact burns EXPERT EDUCATIONAL VIDEO SESSIONS Utility of Point-of-Care Fluorescence for Detection of Elevated Bacterial Burden in an Outpatient Wound Care Setting Charles Andersen, MD, FACS, MAPWCA Chief, Vascular/ Endovascular/ Limb Preservation, Surgery Service (Emeritus), Chief Wound Care Service MAMC Medical Director Wound Care Clinic, Madigan Army Medical Center, Tacoma, WA Duration: 15 minutes Talk Overview: Elevated bacterial

WOUNDSOURCE WEBINAR

View details on the Reimbursement Pathway for the MolecuLight procedure, as well as CME Resources, Training & Education support and

Clinical Research.

ADVANCED WOUND CARE

The MolecuLight i:X Wound Imaging Device allows clinicians to quickly, safely, and easily visualize bacteria 2 and measure wounds 7 at the point of care, so they have maximum insights for accurate treatment selection and accelerated healing. CASE STUDY. WOUND ASSESSMENT TOOL The use of the MolecuLight i:X in managing burns: a pilot study. Journal of Burn Care & Research, 2017, 39 (1), 154-161. doi: 10.1097/BCR.0000000000000565. Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Presented

at Wounds UK 2016.

CLINICAL IMAGE GALLERY OF FLUORESCENCE IMAGES Clinical Image Gallery of Fluorescence Images. Below are a series of images/videos highlighting how the MolecuLight i:X helped clinicians detect fluorescent bacteria and measure wounds to facilitate evidence-based clinician decision making. Search for:

VISUALIZE BACTERIA

The MolecuLight i:X is a handheld fluorescence imaging device that provides instant visual detection and documentation of potentially harmful bacteria in wounds that would otherwise be invisible. 1 The MolecuLight i:X emits a precise wavelength of safe violet light, which interacts with the wound tissue and bacteria causing the wound and

WOUNDSOURCE WEBINAR

The MolecuLight i:X for point-of-care detection of elevated bacterial burden in wounds – in real-time MOLECULIGHT ANNOUNCES CMS HAS ASSIGNED AN APC New Code Enables Reimbursement to Hospital Outpatient Centers Using MolecuLight i:X Toronto, CANADA – (June 11, 2020) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces that the Centers for Medicare & Medicaid Services (CMS) has assigned an Ambulatory Payment Classification (APC) code 5722 for the MolecuLight i:X A PROSPECTIVE MULTISITE OBSERVATIONAL STUDY INCORPORATING ABSTRACT Introduction. The UPPER/LOWER infection checklists look for signs and symptoms of local/superficial infection (UPPER) and deep infection (LOWER) to assist clinicians in identifying and distinguishing between these infection levels, facilitating appropriate treatment. The presence of 3 or more UPPER or LOWER criteria is indicative of infection. Objective. This study evaluated

the

POINT OF CARE IDENTIFICATION Point of Care Identification of. Pseudomonas Aeruginosa. Case Study. Pseudomonas aeruginosa is one of the most common pathogens found in chronic leg ulcers. 1 It frequently leads to stalled wound healing and its unique intrinsic and acquired antibiotic resistances make early identification and selection of Pseudomonas -specific treatment

ADVANCED WOUND CARE

Intended Use & Indication for Use. The MolecuLight i:X is intended for use as a handheld imaging tool that allows clinicians diagnosing and treating skin wounds, at the point of care, to: (iii) View and digitally record images of fluorescence emitted from a wound when exposed to an excitation light. REIMBURSEMENT PATHWAY FOR FLUORESCENCE IMAGING AND Reimbursement Pathway for Fluorescence Imaging and Detection of Wounds Containing Bacterial Burden (>104 CFU/g)* * when used in combination with clinical signs and symptoms There are CPT codes and an APC assignment specific to the procedure for “fluorescence wound imaging for bacterial presence, location, and load”1,2. The MolecuLight i:X® is the only fluorescence imaging device

ADVANCED WOUND CARE

The MolecuLight i:X Wound Imaging Device allows clinicians to quickly, safely, and easily visualize bacteria 2 and measure wounds 7 at the point of care, so they have maximum insights for accurate treatment selection and accelerated healing. CASE STUDY. WOUND ASSESSMENT TOOL The use of the MolecuLight i:X in managing burns: a pilot study. Journal of Burn Care & Research, 2017, 39 (1), 154-161. doi: 10.1097/BCR.0000000000000565. Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Presented

at Wounds UK 2016.

CLINICAL IMAGE GALLERY OF FLUORESCENCE IMAGES Clinical Image Gallery of Fluorescence Images. Below are a series of images/videos highlighting how the MolecuLight i:X helped clinicians detect fluorescent bacteria and measure wounds to facilitate evidence-based clinician decision making. Search for:

VISUALIZE BACTERIA

The MolecuLight i:X is a handheld fluorescence imaging device that provides instant visual detection and documentation of potentially harmful bacteria in wounds that would otherwise be invisible. 1 The MolecuLight i:X emits a precise wavelength of safe violet light, which interacts with the wound tissue and bacteria causing the wound and

WOUNDSOURCE WEBINAR

The MolecuLight i:X for point-of-care detection of elevated bacterial burden in wounds – in real-time MOLECULIGHT ANNOUNCES CMS HAS ASSIGNED AN APC New Code Enables Reimbursement to Hospital Outpatient Centers Using MolecuLight i:X Toronto, CANADA – (June 11, 2020) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces that the Centers for Medicare & Medicaid Services (CMS) has assigned an Ambulatory Payment Classification (APC) code 5722 for the MolecuLight i:X A PROSPECTIVE MULTISITE OBSERVATIONAL STUDY INCORPORATING ABSTRACT Introduction. The UPPER/LOWER infection checklists look for signs and symptoms of local/superficial infection (UPPER) and deep infection (LOWER) to assist clinicians in identifying and distinguishing between these infection levels, facilitating appropriate treatment. The presence of 3 or more UPPER or LOWER criteria is indicative of infection. Objective. This study evaluated

the

POINT OF CARE IDENTIFICATION Point of Care Identification of. Pseudomonas Aeruginosa. Case Study. Pseudomonas aeruginosa is one of the most common pathogens found in chronic leg ulcers. 1 It frequently leads to stalled wound healing and its unique intrinsic and acquired antibiotic resistances make early identification and selection of Pseudomonas -specific treatment

ADVANCED WOUND CARE

Intended Use & Indication for Use. The MolecuLight i:X is intended for use as a handheld imaging tool that allows clinicians diagnosing and treating skin wounds, at the point of care, to: (iii) View and digitally record images of fluorescence emitted from a wound when exposed to an excitation light. REIMBURSEMENT PATHWAY FOR FLUORESCENCE IMAGING AND Reimbursement Pathway for Fluorescence Imaging and Detection of Wounds Containing Bacterial Burden (>104 CFU/g)* * when used in combination with clinical signs and symptoms There are CPT codes and an APC assignment specific to the procedure for “fluorescence wound imaging for bacterial presence, location, and load”1,2. The MolecuLight i:X® is the only fluorescence imaging device WHAT IS THE MOLECULIGHT I:X PROCEDURE? What is the MolecuLight i:X procedure? This 7-minute presentation will cover: How the MolecuLight i:X works. Detecting wounds with elevated bacterial loads. What the wound care clinical workflow looks like with the MolecuLight i:X. Typical cost savings. Reimbursement for the fluorescence imaging procedure. Fluorescence imaging & wound

measurement.

PRESS RELEASES

Press Release: MolecuLight receives $990,000 from FedDev Ontario to complete commercialization of a new clinical wound imaging technology. November 7, 2014 — PRESS RELEASE. Press Release: MolecuLight announces research collaboration MOLECULIGHT EXECUTIVE TEAM MolecuLight Inc. is a privately owned, Canadian medical imaging company founded by Dr. Ralph DaCosta and incorporated on June 1, 2012. The company’s first product, the MolecuLight i:X, is a first-of-its kind handheld imaging device based on Dr. DaCosta’s invention. MolecuLight is based in Toronto, Canada. FREQUENTLY ASKED QUESTIONS (FAQ) In a darkened room, or using a DarkDrape™, the MolecuLight i:X shines a safe violet excitation light (405 nm) on a wound. This causes wound components (skin, slough, blood, bacteria, etc.) to fluoresce (or emit light) in different colours 1–4 .The i:X device displays and captures images of the most informative of these fluorescent

colours.

AMA ISSUES CATEGORY III CPT CODE FOR REAL TIME Reimbursement Pathway Established for MolecuLight’s i:X Procedure in Wound Care TORONTO, Canada – (February 13, 2020) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time detection of bacteria in wounds, announced that the American Medical Association (AMA) has issued two new CPT category lll codes to enable a reimbursement pathway for point-of UTILITY OF MOLECULIGHT FOR WOUND CARE PATIENTS The MolecuLight i:X is a hand-held imaging device that uses a safe violet light to help wound care professionals detect bacteria in your wound and to measure the size of your wound.. The MolecuLight i:X captures both images and videos that can be saved with your medical records to track how your wound is healing. Taking images with the MolecuLight i:X gives your wound care provider information MOLECULIGHT I:X QUICK START GUIDE a. Ensurei:X is OFF or turn device OFF and Display Screen OFF. b. Use a disinfecting wipe to preclean the i:X. d. Use lens towelette to clean all glass surfaces. e. Check that all windows are THE USE OF THE MOLECULIGHT BACTERIAL CAMERA IN THE Fluorescence imaging targets swabbing to region of bioburden Standard Imaging Mode Fluorescence Imaging Mode 85-year-old male suffered deep dermal and full thickness contact burns EXPERT EDUCATIONAL VIDEO SESSIONS Utility of Point-of-Care Fluorescence for Detection of Elevated Bacterial Burden in an Outpatient Wound Care Setting Charles Andersen, MD, FACS, MAPWCA Chief, Vascular/ Endovascular/ Limb Preservation, Surgery Service (Emeritus), Chief Wound Care Service MAMC Medical Director Wound Care Clinic, Madigan Army Medical Center, Tacoma, WA Duration: 15 minutes Talk Overview: Elevated bacterial

WOUNDSOURCE WEBINAR

View details on the Reimbursement Pathway for the MolecuLight procedure, as well as CME Resources, Training & Education support and

Clinical Research.

Cookie Policy

This website uses cookies to enhance your user experience. Learn more DeclineAllow cookies Skip to main content

* Wound Care

*

Products

MolecuLight _I:X_

*

Clinical Evidence

Clinical Overview Case Studies Publications

Posters

Clinical Image Gallery

*

Training & Support

Training Resources User

Documentation FAQ

*

About Us

Executive Team Conferences & Events Press Releases

Careers

*

Contact Us

*

Request A Demo

*

Request A Demo

Phone: +1 647-362-4684

ROW

HOME

WOUND IMAGING DEVICE The first-ever wound assessment device to provide real-time imaging of bacteria distribution at the point of care.

Learn More

* 1

MOLECULIGHT _I:__X_ MAY HELP AT EVERY STAGE OF WOUND CARE

">

Assessment

Cleaning

Debridement

Sampling

Documentation

Treatment Selection

Antibiotic Stewardship

Patient Engagement

ASSESSMENT

Visualize fluorescent bacteria and measure wound surface area in real-time to understand the status of the wound more fully.1,3

CLEANING

Allows clinicians to focus cleaning in areas where fluorescent bacteria are located and optimize wound bed preparation.10

DEBRIDEMENT

Guides more efficient and targeted debridement.2,6,7

SAMPLING

Guides where to sample; 54% more accurate swabbing compared to the

Levine technique.3

DOCUMENTATION

Provides objective visual documentation of the presence of fluorescent bacteria and the surface area of the wound.2,9

TREATMENT SELECTION

Comparing fluorescent bacteria and wound surface area at each visit may provide real-time objective feedback on impact of treatment

plan.1,2,4

ANTIBIOTIC STEWARDSHIP Supports more responsible antibiotic decision making and

selection.6,8,9

PATIENT ENGAGEMENT

Patients easily see and understand why a clinician is taking certain action to clean, debride, and treat a wound in a specific way.4,5

ASSESSMENT

Visualize fluorescent bacteria and measure wound surface area in real-time to understand the status of the wound more fully.1,3

CLEANING

Allows clinicians to focus cleaning in areas where fluorescent bacteria are located and optimize wound bed preparation.10

DEBRIDEMENT

Guides more efficient and targeted debridement.2,6,7

SAMPLING

Guides where to sample; 54% more accurate swabbing compared to the

Levine technique.3

DOCUMENTATION>

Provides objective visual documentation of the presence of fluorescent bacteria and the surface area of the wound.2,9

TREATMENT SELECTION

Comparing fluorescent bacteria and wound surface area at each visit may provide real-time objective feedback on impact of treatment

plan.1,2,4

ANTIBIOTIC STEWARDSHIP Supports more responsible antibiotic decision making and

selection.6,8,9

PATIENT ENGAGEMENT

Patients easily see and understand why a clinician is taking certain action to clean, debride, and treat a wound in a specific way.4,5

* 1

* 2

* 3

* 4

* 5

* 6

* 7

* 8

Watch Video

MAKING A DIFFERENCE IN WOUND CARE

UP TO

50%

MORE ACCURATE SWABBING3

Learn More

UP TO

100%

POSITIVE PREDICTIVE VALUE4

Learn More

UP TO

9X

FASTER HEALING2

Learn More

PRESS RELEASE

CLINICAL RESULTS FROM THE MOLECULIGHT _I:X_® FLUORESCENCE IMAGING SYSTEM ARE FEATURED IN TWO CLINICAL TALKS AND SEVEN POSTERS AT THE SAWC FALL 2019 ANNUAL CONFERENCE Multiple Trials Illustrate the Significant Clinical Benefit of MolecuLight’s Point-of-Care Fluorescence Imaging Device for Chronic

Wound Management

LAS VEGAS, USA and TORONTO, Canada – (October 11, 2019) MolecuLight Inc., the world’s leader...

Read More

WATCH MOLECULIGHT _I:__X_ IN ACTION The MolecuLight _I:__X_ Wound Imaging Device allows clinicians to quickly, safely, and easily visualize bacteria2 and measure wounds7 at the point of care, so they have maximum insights for accurate treatment selection and accelerated healing.

CASE STUDY

REAL-TIME DETECTION OF ASYMPTOMATIC BIOBURDEN WITH THE MOLECULIGHT _I:__X_ REVEALED NEED FOR SYSTEMIC ANTIBIOTICS AND IMMEDIATE HOSPITALIZATION Use of the MolecuLight _I:__X_ to image for bacterial fluorescence, in conjunction with clinical signs & symptoms, adds an additional bacterial-specific piece of information that can be captured and considered in real-time.

See Full Case Study

TESTIMONIALS

"The MolecuLight _I:X_ gives clinicians the ability to visualize and therefore target treatment towards clinically undetectable critical colonization. This user friendly point-of-care device is an exciting addition to our wound care protocol." David Russell, MD // Leeds Teaching Hospitals, Leeds, UK "The MolecuLight _I:X_ has transformed my clinical decision making. MolecuLight _I:X_ helps reveal the unexpected and eliminates guess

work."

Rosemary Hill, BSN CWOCN CETN(C) // Vancouver Coastal Health, North

Vancouver, Canada

"The MolecuLight _I:X_ completely changed my decision making and resulted in not only time and cost savings but also improved patient

outcomes.”

Lt Col Steven Jeffery // The Royal Centre for Defence Medicine,

Birmingham, UK

"The MolecuLight _I:X_ gives clinicians the ability to visualize and therefore target treatment towards clinically undetectable critical colonization. This user friendly point-of-care device is an exciting addition to our wound care protocol." David Russell, MD // Leeds Teaching Hospitals, Leeds, UK "The MolecuLight _I:X_ has transformed my clinical decision making. MolecuLight _I:X_ helps reveal the unexpected and eliminates guess

work."

Rosemary Hill, BSN CWOCN CETN(C) // Vancouver Coastal Health, North

Vancouver, Canada

"The MolecuLight _I:X_ completely changed my decision making and resulted in not only time and cost savings but also improved patient

outcomes.”

Lt Col Steven Jeffery // The Royal Centre for Defence Medicine,

Birmingham, UK

"The MolecuLight _I:X_ gives clinicians the ability to visualize and therefore target treatment towards clinically undetectable critical colonization. This user friendly point-of-care device is an exciting addition to our wound care protocol." David Russell, MD // Leeds Teaching Hospitals, Leeds, UK

* 1

* 2

* 3

FIND OUT HOW TO MAKE A DIFFERENCE IN WOUND CARE Request InformationRequest DemoRequest Quote REQUEST MORE INFORMATION

Name *

Title

Select one of the following...Mr.Ms.Mrs.Dr.PhDMDProf. Select one of the following...

Mr.

Ms.

Mrs.

Dr.

PhD

MD

Prof.

Email Address *

Company/Organization *

Phone

Address

City

Province/State *

Country *

Select one of the

following...AfghanistanAlbaniaAlgeriaAndorraAngolaAntigua & BarbudaArgentinaArmeniaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBhutanBoliviaBosnia & HerzegovinaBotswanaBrazilBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCentral African RepublicChadChileChinaColombiaComorosCongoCongo Democratic RepublicCosta RicaCote d'IvoireCroatiaCubaCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEast TimorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFijiFinlandFranceGabonGambiaGeorgiaGermanyGhanaGreeceGrenadaGuatemalaGuineaGuinea-BissauGuyanaHaitiHondurasHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiKorea

NorthKorea

SouthKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMauritaniaMauritiusMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMoroccoMozambiqueMyanmar (Burma)NamibiaNauruNepalThe NetherlandsNew ZealandNicaraguaNigerNigeriaNorwayOmanPakistanPalauPalestinian State*PanamaPapua New GuineaParaguayPeruThe PhilippinesPolandPortugalQatarRomaniaRussiaRwandaSt. Kitts & NevisSt. LuciaSt. Vincent & The GrenadinesSamoaSan MarinoSao Tome & PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth

SudanSpainSri

LankaSudanSurinameSwazilandSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTogoTongaTrinidad & TobagoTunisiaTurkeyTurkmenistanTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited States of AmericaUruguayUzbekistanVanuatuVatican City (Holy See)VenezuelaVietnamYemenZambiaZimbabwe Select one of the following...

Afghanistan

Albania

Algeria

Andorra

Angola

Antigua & Barbuda

Argentina

Armenia

Australia

Austria

Azerbaijan

Bahamas

Bahrain

Bangladesh

Barbados

Belarus

Belgium

Belize

Benin

Bhutan

Bolivia

Bosnia & Herzegovina

Botswana

Brazil

Brunei

Bulgaria

Burkina Faso

Burundi

Cambodia

Cameroon

Canada

Cape Verde

Central African Republic

Chad

Chile

China

Colombia

Comoros

Congo

Congo Democratic Republic

Costa Rica

Cote d'Ivoire

Croatia

Cuba

Cyprus

Czech Republic

Denmark

Djibouti

Dominica

Dominican Republic

Ecuador

East Timor

Egypt

El Salvador

Equatorial Guinea

Eritrea

Estonia

Ethiopia

Fiji

Finland

France

Gabon

Gambia

Georgia

Germany

Ghana

Greece

Grenada

Guatemala

Guinea

Guinea-Bissau

Guyana

Haiti

Honduras

Hungary

Iceland

India

Indonesia

Iran

Iraq

Ireland

Israel

Italy

Jamaica

Japan

Jordan

Kazakhstan

Kenya

Kiribati

Korea North

Korea South

Kosovo

Kuwait

Kyrgyzstan

Laos

Latvia

Lebanon

Lesotho

Liberia

Libya

Liechtenstein

Lithuania

Luxembourg

Macedonia

Madagascar

Malawi

Malaysia

Maldives

Mali

Malta

Marshall Islands

Mauritania

Mauritius

Mexico

Micronesia

Moldova

Monaco

Mongolia

Montenegro

Morocco

Mozambique

Myanmar (Burma)

Namibia

Nauru

Nepal

The Netherlands

New Zealand

Nicaragua

Niger

Nigeria

Norway

Oman

Pakistan

Palau

Palestinian State*

Panama

Papua New Guinea

Paraguay

Peru

The Philippines

Poland

Portugal

Qatar

Romania

Russia

Rwanda

St. Kitts & Nevis

St. Lucia

St. Vincent & The Grenadines

Samoa

San Marino

Sao Tome & Principe

Saudi Arabia

Senegal

Serbia

Seychelles

Sierra Leone

Singapore

Slovakia

Slovenia

Solomon Islands

Somalia

South Africa

South Sudan

Spain

Sri Lanka

Sudan

Suriname

Swaziland

Sweden

Switzerland

Syria

Taiwan

Tajikistan

Tanzania

Thailand

Togo

Tonga

Trinidad & Tobago

Tunisia

Turkey

Turkmenistan

Tuvalu

Uganda

Ukraine

United Arab Emirates

United Kingdom

United States of America

Uruguay

Uzbekistan

Vanuatu

Vatican City (Holy See)

Venezuela

Vietnam

Yemen

Zambia

Zimbabwe

Message

I'd like to receive the following: BrochurePublications and PosterseNewsletterOn-Site DemonstrationQuotation

* Required fields

REQUEST A DEMO

Thank you your interest in the MolecuLight i:X. Please fill out the form below and we will contact you to set up a demonstration.

Name *

Title

Select one of the following...Mr.Ms.Mrs.Dr.PhDMDProf. Select one of the following...

Mr.

Ms.

Mrs.

Dr.

PhD

MD

Prof.

Email Address *

Company/Organization *

Phone

Address

City

Province/State *

Country *

Select one of the

following...AfghanistanAlbaniaAlgeriaAndorraAngolaAntigua & BarbudaArgentinaArmeniaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBhutanBoliviaBosnia & HerzegovinaBotswanaBrazilBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCentral African RepublicChadChileChinaColombiaComorosCongoCongo Democratic RepublicCosta RicaCote d'IvoireCroatiaCubaCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEast TimorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFijiFinlandFranceGabonGambiaGeorgiaGermanyGhanaGreeceGrenadaGuatemalaGuineaGuinea-BissauGuyanaHaitiHondurasHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiKorea

NorthKorea

SouthKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMauritaniaMauritiusMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMoroccoMozambiqueMyanmar (Burma)NamibiaNauruNepalThe NetherlandsNew ZealandNicaraguaNigerNigeriaNorwayOmanPakistanPalauPalestinian State*PanamaPapua New GuineaParaguayPeruThe PhilippinesPolandPortugalQatarRomaniaRussiaRwandaSt. Kitts & NevisSt. LuciaSt. Vincent & The GrenadinesSamoaSan MarinoSao Tome & PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth

SudanSpainSri

LankaSudanSurinameSwazilandSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTogoTongaTrinidad & TobagoTunisiaTurkeyTurkmenistanTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited States of AmericaUruguayUzbekistanVanuatuVatican City (Holy See)VenezuelaVietnamYemenZambiaZimbabwe Select one of the following...

Afghanistan

Albania

Algeria

Andorra

Angola

Antigua & Barbuda

Argentina

Armenia

Australia

Austria

Azerbaijan

Bahamas

Bahrain

Bangladesh

Barbados

Belarus

Belgium

Belize

Benin

Bhutan

Bolivia

Bosnia & Herzegovina

Botswana

Brazil

Brunei

Bulgaria

Burkina Faso

Burundi

Cambodia

Cameroon

Canada

Cape Verde

Central African Republic

Chad

Chile

China

Colombia

Comoros

Congo

Congo Democratic Republic

Costa Rica

Cote d'Ivoire

Croatia

Cuba

Cyprus

Czech Republic

Denmark

Djibouti

Dominica

Dominican Republic

Ecuador

East Timor

Egypt

El Salvador

Equatorial Guinea

Eritrea

Estonia

Ethiopia

Fiji

Finland

France

Gabon

Gambia

Georgia

Germany

Ghana

Greece

Grenada

Guatemala

Guinea

Guinea-Bissau

Guyana

Haiti

Honduras

Hungary

Iceland

India

Indonesia

Iran

Iraq

Ireland

Israel

Italy

Jamaica

Japan

Jordan

Kazakhstan

Kenya

Kiribati

Korea North

Korea South

Kosovo

Kuwait

Kyrgyzstan

Laos

Latvia

Lebanon

Lesotho

Liberia

Libya

Liechtenstein

Lithuania

Luxembourg

Macedonia

Madagascar

Malawi

Malaysia

Maldives

Mali

Malta

Marshall Islands

Mauritania

Mauritius

Mexico

Micronesia

Moldova

Monaco

Mongolia

Montenegro

Morocco

Mozambique

Myanmar (Burma)

Namibia

Nauru

Nepal

The Netherlands

New Zealand

Nicaragua

Niger

Nigeria

Norway

Oman

Pakistan

Palau

Palestinian State*

Panama

Papua New Guinea

Paraguay

Peru

The Philippines

Poland

Portugal

Qatar

Romania

Russia

Rwanda

St. Kitts & Nevis

St. Lucia

St. Vincent & The Grenadines

Samoa

San Marino

Sao Tome & Principe

Saudi Arabia

Senegal

Serbia

Seychelles

Sierra Leone

Singapore

Slovakia

Slovenia

Solomon Islands

Somalia

South Africa

South Sudan

Spain

Sri Lanka

Sudan

Suriname

Swaziland

Sweden

Switzerland

Syria

Taiwan

Tajikistan

Tanzania

Thailand

Togo

Tonga

Trinidad & Tobago

Tunisia

Turkey

Turkmenistan

Tuvalu

Uganda

Ukraine

United Arab Emirates

United Kingdom

United States of America

Uruguay

Uzbekistan

Vanuatu

Vatican City (Holy See)

Venezuela

Vietnam

Yemen

Zambia

Zimbabwe

Message

I would like exclusive access to the latest MolecuLight content.

* Required fields

REQUEST QUOTE

Please fill out the form below to request a quotation for the MolecuLight _I:X_ Imaging Device.

Name *

Title

Select one of the following...Mr.Ms.Mrs.Dr.PhDMDProf. Select one of the following...

Mr.

Ms.

Mrs.

Dr.

PhD

MD

Prof.

Email Address *

Company/Organization *

Phone

Address

City

Province/State *

Country *

Select one of the

following...AfghanistanAlbaniaAlgeriaAndorraAngolaAntigua & BarbudaArgentinaArmeniaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBhutanBoliviaBosnia & HerzegovinaBotswanaBrazilBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCentral African RepublicChadChileChinaColombiaComorosCongoCongo Democratic RepublicCosta RicaCote d'IvoireCroatiaCubaCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEast TimorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFijiFinlandFranceGabonGambiaGeorgiaGermanyGhanaGreeceGrenadaGuatemalaGuineaGuinea-BissauGuyanaHaitiHondurasHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiKorea

NorthKorea

SouthKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMauritaniaMauritiusMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMoroccoMozambiqueMyanmar (Burma)NamibiaNauruNepalThe NetherlandsNew ZealandNicaraguaNigerNigeriaNorwayOmanPakistanPalauPalestinian State*PanamaPapua New GuineaParaguayPeruThe PhilippinesPolandPortugalQatarRomaniaRussiaRwandaSt. Kitts & NevisSt. LuciaSt. Vincent & The GrenadinesSamoaSan MarinoSao Tome & PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth

SudanSpainSri

LankaSudanSurinameSwazilandSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTogoTongaTrinidad & TobagoTunisiaTurkeyTurkmenistanTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited States of AmericaUruguayUzbekistanVanuatuVatican City (Holy See)VenezuelaVietnamYemenZambiaZimbabwe Select one of the following...

Afghanistan

Albania

Algeria

Andorra

Angola

Antigua & Barbuda

Argentina

Armenia

Australia

Austria

Azerbaijan

Bahamas

Bahrain

Bangladesh

Barbados

Belarus

Belgium

Belize

Benin

Bhutan

Bolivia

Bosnia & Herzegovina

Botswana

Brazil

Brunei

Bulgaria

Burkina Faso

Burundi

Cambodia

Cameroon

Canada

Cape Verde

Central African Republic

Chad

Chile

China

Colombia

Comoros

Congo

Congo Democratic Republic

Costa Rica

Cote d'Ivoire

Croatia

Cuba

Cyprus

Czech Republic

Denmark

Djibouti

Dominica

Dominican Republic

Ecuador

East Timor

Egypt

El Salvador

Equatorial Guinea

Eritrea

Estonia

Ethiopia

Fiji

Finland

France

Gabon

Gambia

Georgia

Germany

Ghana

Greece

Grenada

Guatemala

Guinea

Guinea-Bissau

Guyana

Haiti

Honduras

Hungary

Iceland

India

Indonesia

Iran

Iraq

Ireland

Israel

Italy

Jamaica

Japan

Jordan

Kazakhstan

Kenya

Kiribati

Korea North

Korea South

Kosovo

Kuwait

Kyrgyzstan

Laos

Latvia

Lebanon

Lesotho

Liberia

Libya

Liechtenstein

Lithuania

Luxembourg

Macedonia

Madagascar

Malawi

Malaysia

Maldives

Mali

Malta

Marshall Islands

Mauritania

Mauritius

Mexico

Micronesia

Moldova

Monaco

Mongolia

Montenegro

Morocco

Mozambique

Myanmar (Burma)

Namibia

Nauru

Nepal

The Netherlands

New Zealand

Nicaragua

Niger

Nigeria

Norway

Oman

Pakistan

Palau

Palestinian State*

Panama

Papua New Guinea

Paraguay

Peru

The Philippines

Poland

Portugal

Qatar

Romania

Russia

Rwanda

St. Kitts & Nevis

St. Lucia

St. Vincent & The Grenadines

Samoa

San Marino

Sao Tome & Principe

Saudi Arabia

Senegal

Serbia

Seychelles

Sierra Leone

Singapore

Slovakia

Slovenia

Solomon Islands

Somalia

South Africa

South Sudan

Spain

Sri Lanka

Sudan

Suriname

Swaziland

Sweden

Switzerland

Syria

Taiwan

Tajikistan

Tanzania

Thailand

Togo

Tonga

Trinidad & Tobago

Tunisia

Turkey

Turkmenistan

Tuvalu

Uganda

Ukraine

United Arab Emirates

United Kingdom

United States of America

Uruguay

Uzbekistan

Vanuatu

Vatican City (Holy See)

Venezuela

Vietnam

Yemen

Zambia

Zimbabwe

Message

I would like exclusive access to the latest MolecuLight content.

* Required fields

STAY ON TOP OF THE LATEST ADVANCEMENTS IN WOUND CARE Follow us on Follow Us

on

UPDATES FROM TWITTER

- October 24, 2019

RT @Wound_Guy : “Real time bacterial fluorescence imaging (MolecuLight) facilitated evidence-based deployment of systemic antibiotics and prevented their unnecessary use.” Hill 2018. This is antibiotic stewardship in action. #antibiotics #healthcare #nursing #wounds

__

__1

__

- October 24, 2019

RT @PodiatryToday : New DPM Blog by Barbara Aung, DPM: Emerging Insights On The Diagnostic Benefits Of Fluorescence Imaging In Wound Care https://t.co/g1ouSE7er0 @APMA @ACFAS https://t.co/QHJryu4E76

__

__1

__

- October 24, 2019

RT @SergylB : Diagnostic biomarkers and fluorescence imaging may have the potential to advance wound care - Venous News https://t.co/bELC1NxPMX

__

__2

__

See more tweets

MOLECULIGHT HEADQUARTERS 425 University Avenue

Suite 700

Toronto, ON  M5G 1T6

Canada

US Address

MolecuLight Corp.

2403 Sidney Street,

Suite 209

Pittsburgh, PA 15203

T. +1 647-362-4684

North American Toll Free:

1-877-818-4360

F. +1 647-362-4730

E: info@moleculight.com

SITEMAP

* MolecuLight _I:X_

* Clinical Overview

* Case Studies

* Publications

* Posters

* Clinical Image Gallery * Training Resources * User Documentation

* FAQ

* Executive Team

* Conferences & Events

* Press Releases

* Contact Us

* Careers

MolecuLight is a proud corporate member of:

ROW

� 2019 MolecuLight® Inc. All Rights Reserved. The MolecuLight _I:X_™ Imaging Device is approved by Health Canada and has CE marking for sale in Canada and the European Union. The MolecuLight _I:X_™ Imaging Device has received FDA clearance. MolecuLight® and Look to Heal® are registered trademarks in Canada,

the US and the EU.

Privacy Policy

|  Terms of Use

REFERENCES

* Wu YC, Smith M, Chu A, Lindvere-Teene L, Starr D, Tapang K, Wong O, Linden R, DaCosta RS. Handheld fluorescence imaging device detects subclinical wound infection in an asymptomatic patient with chronic diabetic foot ulcer: a case report. International Wound Journal, 2016, 13(4), 449-53. doi: 10.1111/iwj.12451. * DaCosta RS, Kulbatski I, Lindvere-Teene L, Starr D, Blackmore K, Silver JI, Opoku J, Wu YC, Medeiros PJ, Xu W, Xu L, Wilson BC, Rosen C, Linden R. Point-of-care autofluorescence imaging for real-time sampling and treatment guidance of bioburden in chronic wounds: first-in-human results. PLOS ONE, 2015, 10(2). doi: 10.1371/journal.pone.0116623. * Ottolino-Perry K, Chamma E, Blackmore KM, Lindvere-Teene L, Starr D, Tapang K, Rosen CF, Pitcher B, Panzarella T, Linden R, DaCosta RS. Improved detection of clinically relevant wound bacteria using autofluorescence image-guided sampling in diabetic foot ulcers. International Wound Journal, 2017, 14(5), 833-841. doi:

10.1111/iwj.12717.

* Rennie MY, Lindvere-Teene L, Tapang K, Linden R. Point-of-care fluorescence imaging predicts the presence of pathogenic bacteria in wounds: a clinical study. Journal of Wound Care, 2017, 26(8), 452-460. doi: 10.12968/jowc.2017.26.8.452. * Raizman R. Point-of-care fluorescence imaging device guides care and patient education in obese patients with surgical site infections. Presented at CAWC 2016. Proceedings of the Annual Canadian Association of Wound Care Conference; 2016 Nov 3-6, Niagara Falls, ON, Canada. * Jeffery S. Utility of point-of-care autofluorescence imaging device in successful closure of major limb amputations – a case study. Presented at MHSRS 2016. Proceedings of the Military Health System Research Symposium; 2016 Aug 15-18; Kissimmee, FL, USA. * Dunham D, Teene L. Objective wound measurement software on a point-of-care, hand-held fluorescence imaging device: verification of measurement accuracy and repeatability. Presented at EWMA 2018. Proceedings of the Annual European Wound Management Association Conference; 2018 May 9-11; Krakow, Poland. * Wu YC, Kulbatski I, Medeiros PJ, Maeda A, Bu J, Xu L, Chen Y, DaCosta RS. Autofluorescence imaging device for real-time detection and tracking of pathogenic bacteria in a mouse skin wound model: preclinical feasibility studies. Journal of Biomedical Optics, 2014, 19(8). doi: 10.1117/1.JBO.19.8.085002. * Raizman R, DaCosta RS. Handheld real-time fluorescence imaging of bacteria guides treatment selection and timing of dressing changes in inpatients undergoing negative pressure wound therapy.  Presented at IWH 2016. Proceedings of the Innovations in Wound Healing Conference; 2016 Dec 8-11, Key Largo, FL, USA. * Landis S, Rennie MY, Blumenthal E, Jeffery S. Use of fluorescence imaging in visualizing bacteria in chronic ulcers and traumatic soft tissue damage. Presented at AMSUS 2016. Proceedings of the Annual Meeting of the Society of Federal Health Professionals; 2016 Nov 29-Dec 2; National Harbor, MD, USA. * Landis S. Mapping venous ulcers using bacterial autofluorescence (BAF) to identify subgroups at risk of infection post debridement. Presented at CAWC 2016. Proceedings of the Annual Canadian Association of Wound Care Conference; 2016 Nov 3-6, Niagara Falls, ON, Canada. * Hill R, Douglas JJ. Effect of bacterial fluorescence imaging on patient care and wound management in a hospital setting: a pilot study. Presented at SAWC Spring 2017. Proceedings of the Annual Symposium on Advanced Wound Care; 2017 Apr 5-9; San Diego, CA, USA. * Hill R, Douglas JJ. Real-time bacterial fluorescence imaging guides antimicrobial stewardship in patients with diverse wounds. Presented at SAWC Spring 2017. Proceedings of the Annual Symposium on Advanced Wound Care; 2017 Apr 5-9; San Diego, CA, USA. * MolecuLight Inc. PN 1189 MolecuLight i:X User Manual. 2016. * Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Presented at Wounds UK 2016. Proceedings of the Annual Wounds UK Conference; 2016 Nov 14-16; Harrogate, UK.

Cancel Continue

Request Quote Request Demo Request Info